The estimated Net Worth of Graham Peter Lidgard is at least $34 Million dollars as of 11 March 2021. Graham Lidgard owns over 43,241 units of Exact Sciences stock worth over $5,232,705 and over the last 15 years he sold EXAS stock worth over $26,720,490. In addition, he makes $2,084,980 as Senior Vice President and Chief Scientific Officer at Exact Sciences.
Graham has made over 46 trades of the Exact Sciences stock since 2011, according to the Form 4 filled with the SEC. Most recently he exercised 43,241 units of EXAS stock worth $1,126,860 on 11 March 2021.
The largest trade he's ever made was exercising 311,112 units of Exact Sciences stock on 11 November 2016 worth over $896,003. On average, Graham trades about 26,399 units every 60 days since 2009. As of 11 March 2021 he still owns at least 81,608 units of Exact Sciences stock.
You can see the complete history of Graham Lidgard stock trades at the bottom of the page.
Dr. Graham Peter Lidgard Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. He joined us from Nanogen Inc., a medical diagnostics products company, where he was senior vice president of research and development from 2003 to 2009. Prior to joining Nanogen, Dr. Lidgard led the research and development organization at Gen-Probe Inc., a molecular diagnostics company, which developed that company's Procleix blood screening products and Aptima sexually transmitted disease products, as well as the system development group at Gen-Probe that developed its fully automated Tigris system. Prior to joining Gen-Probe in 1995, Dr. Lidgard was co-founder and vice president of product development of Matritech Inc., a developer of diagnostic products for the early detection of bladder cancer. Before he co-founded Matritech, Dr. Lidgard held senior positions at Ciba Corning Diagnostics Corp.'s worldwide diagnostics group. While at Ciba Corning, he was involved in the development of more than 70 510(k)-cleared products. He led the program for the development of the magnetic particle chemiluminescent technology that became the ACS:180 and Centaur systems. Dr. Lidgard earned a bachelor's degree and a doctorate in biological chemistry from the University of Manchester in England.
As the Senior Vice President and Chief Scientific Officer of Exact Sciences, the total compensation of Graham Lidgard at Exact Sciences is $2,084,980. There are 6 executives at Exact Sciences getting paid more, with Kevin Conroy having the highest compensation of $18,716,500.
Graham's mailing address filed with the SEC is C/O EXACT SCIENCES CORP., 5505 ENDEAVOR LANE, MADISON, WI, 53719.
Over the last 21 years, insiders at Exact Sciences have traded over $118,141,352 worth of Exact Sciences stock and bought 191,930 units worth $1,451,887 . The most active insiders traders include Kevin T Conroy, Edwin M Jr Kania, and Maneesh Arora. On average, Exact Sciences executives and independent directors trade stock every 12 days with the average trade being worth of $1,667,056. The most recent stock trade was executed by Brian Baranick on 5 August 2024, trading 2,712 units of EXAS stock currently worth $173,893.
exact sciences is a molecular diagnostics company focused on colorectal cancer. the company has exclusive intellectual property protecting its non-invasive, molecular screening technology for the detection of colorectal cancer. stool-based dna (sdna) technology is included in the colorectal cancer screening guidelines of the american cancer society and the u.s. multi-society task force on colorectal cancer. for more information on exact sciences' noninvasive colon cancer screening test, visit cologuardtest.com
Exact Sciences executives and other stock owners filed with the SEC include: